Teva is primed for a big bounce after years of underperformance, Barclays says

A Teva Pharmaceutical Industries building is seen in Jerusalem December 14, 2017.
Ammar Awad | Reuters

Shares for Teva Pharmaceuticals could jump 31% from here after the company settles a spate of legal issues, according to Barclays.

More In Street Calls

CNBC ProGoldman says buy the pullback in oil and other commodities
CNBC ProCiti cuts year-end S&P 500 target, but sees second-half bounce
CNBC ProHere are Monday's biggest analyst calls: Robinhood, Apple, Oracle, Chewy, Deckers, Amazon & more